Organon & Co. (NYSE:OGN) Hits New 1-Year Low – Here’s What Happened

Organon & Co. (NYSE:OGN)’s stock price reached a new 52-week low on Wednesday . The stock traded as low as $6.16 and last traded at $6.2150, with a volume of 620723 shares trading hands. The stock had previously closed at $6.39.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on OGN. Barclays boosted their target price on shares of Organon & Co. from $7.50 to $8.00 and gave the company an “underweight” rating in a research report on Tuesday, February 24th. Wall Street Zen downgraded shares of Organon & Co. from a “buy” rating to a “hold” rating in a research note on Saturday, January 31st. Finally, Zacks Research lowered shares of Organon & Co. from a “hold” rating to a “strong sell” rating in a report on Thursday, January 29th. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Hold rating and five have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Reduce” and a consensus price target of $8.50.

Organon & Co. Price Performance

The firm has a market cap of $1.62 billion, a P/E ratio of 8.74, a P/E/G ratio of 0.58 and a beta of 0.60. The company has a fifty day moving average of $7.84 and a 200-day moving average of $8.23. The company has a debt-to-equity ratio of 11.47, a current ratio of 1.82 and a quick ratio of 1.23.

Organon & Co. (NYSE:OGN) last issued its quarterly earnings data on Thursday, February 12th. The company reported $0.63 earnings per share for the quarter, missing the consensus estimate of $0.73 by ($0.10). The company had revenue of $1.51 billion for the quarter, compared to the consensus estimate of $1.52 billion. Organon & Co. had a net margin of 3.01% and a return on equity of 122.01%. Organon & Co.’s revenue was down 5.3% on a year-over-year basis. During the same quarter last year, the business posted $0.90 earnings per share. On average, sell-side analysts anticipate that Organon & Co. will post 3.68 EPS for the current fiscal year.

Organon & Co. Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Thursday, March 12th. Investors of record on Monday, February 23rd were given a dividend of $0.02 per share. This represents a $0.08 dividend on an annualized basis and a dividend yield of 1.3%. The ex-dividend date of this dividend was Monday, February 23rd. Organon & Co.’s dividend payout ratio (DPR) is presently 11.27%.

Institutional Investors Weigh In On Organon & Co.

A number of institutional investors have recently added to or reduced their stakes in the company. Sector Gamma AS purchased a new stake in Organon & Co. in the 3rd quarter valued at about $5,807,000. Gotham Asset Management LLC boosted its stake in shares of Organon & Co. by 37.2% in the 3rd quarter. Gotham Asset Management LLC now owns 3,713,204 shares of the company’s stock worth $39,657,000 after buying an additional 1,007,691 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Organon & Co. by 11.3% in the third quarter. Vanguard Group Inc. now owns 35,928,403 shares of the company’s stock valued at $383,715,000 after acquiring an additional 3,650,860 shares in the last quarter. Coldstream Capital Management Inc. grew its holdings in shares of Organon & Co. by 61.6% in the second quarter. Coldstream Capital Management Inc. now owns 22,686 shares of the company’s stock valued at $220,000 after acquiring an additional 8,644 shares in the last quarter. Finally, American Century Companies Inc. increased its position in shares of Organon & Co. by 1,205.1% during the second quarter. American Century Companies Inc. now owns 522,013 shares of the company’s stock valued at $5,053,000 after acquiring an additional 482,016 shares during the last quarter. 77.43% of the stock is owned by institutional investors.

Organon & Co. Company Profile

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.